High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes.

Purpose To investigate the associations between BRCA mutation status and computed tomography (CT) phenotypes of high-grade serous ovarian cancer (HGSOC) and to evaluate CT indicators of cytoreductive outcome and survival in patients with BRCA-mutant HGSOC and those with BRCA wild-type HGSOC. Materials and Methods This HIPAA-compliant, institutional review board-approved retrospective study included 108 patients (33 with BRCA mutant and 75 with BRCA wild-type HGSOC) who underwent CT before primary debulking. Two radiologists independently reviewed the CT findings for various qualitative CT features. Associations between CT features, BRCA mutation status, cytoreductive outcome, and progression-free survival (PFS) were evaluated by using logistic regression and Cox proportional hazards regression, respectively. Results Peritoneal disease (PD) pattern, presence of PD in gastrohepatic ligament, mesenteric involvement, and supradiaphragmatic lymphadenopathy at CT were associated with BRCA mutation status (multiple regression: P < .001 for each CT feature). While clinical and CT features were not associated with cytoreductive outcome for patients with BRCA-mutant HGSOC, presence of PD in lesser sac (odds ratio [OR] = 2.40) and left upper quadrant (OR = 1.19), mesenteric involvement (OR = 7.10), and lymphadenopathy in supradiaphragmatic (OR = 2.83) and suprarenal para-aortic (OR = 4.79) regions were associated with higher odds of incomplete cytoreduction in BRCA wild-type HGSOC (multiple regression: P < .001 each CT feature). Mesenteric involvement at CT was associated with significantly shorter PFS for both patients with BRCA-mutant HGSOC (multiple regression: hazard ratio [HR] = 26.7 P < .001) and those with BRCA wild-type HGSOC (univariate analysis: reader 1, HR = 2.42, P < .001; reader 2, HR = 2.61; P < .001). Conclusion Qualitative CT features differed between patients with BRCA-mutant HGSOC and patients with BRCA wild-type HGSOC. CT indicators of cytoreductive outcome varied according to BRCA mutation status. Mesenteric involvement at CT was an indicator of significantly shorter PFS for both patients with BRCA-mutant HGSOC and those with BRCA wild-type HGSOC. © RSNA, 2017 Online supplemental material is available for this article.

[1]  H. Hricak,et al.  Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery , 2015, European Radiology.

[2]  H. Hricak,et al.  Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study. , 2015, Radiology.

[3]  H. Hricak,et al.  A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. , 2014, Gynecologic oncology.

[4]  D. Levine,et al.  Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency , 2014, Modern Pathology.

[5]  J. Donovan,et al.  The “Definitive” Trial of Surgical Cytoreduction in Advanced-Stage Ovarian Cancer , 2013, International Journal of Gynecologic Cancer.

[6]  V. Grann,et al.  Role of genetic testing for screening and prevention for ovarian cancer: comment on "Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing". , 2013, JAMA internal medicine.

[7]  K. Cibulskis,et al.  Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. , 2012, The Journal of clinical investigation.

[8]  Alexia Iasonos,et al.  Improved survival for BRCA2‐associated serous ovarian cancer compared with both BRCA‐negative and BRCA1‐associated serous ovarian cancer , 2012, Cancer.

[9]  Narciso Olvera,et al.  Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma , 2012, Modern Pathology.

[10]  K. Hess,et al.  Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. , 2011, JAMA.

[11]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[12]  K. Offit,et al.  Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  C. Sima,et al.  The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum. , 2010, Gynecologic oncology.

[14]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[15]  G. Scambia,et al.  Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial , 2009, British Journal of Cancer.

[16]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[17]  Nhu Le,et al.  Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. , 2008, Human pathology.

[18]  B. Karlan,et al.  Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Hart,et al.  The correlation of mammographic-and histologic patterns of breast cancers in BRCA1 gene mutation carriers, compared to age-matched sporadic controls , 2006, European Radiology.

[20]  B. Miller,et al.  Role of CT and MR imaging in predicting optimal cytoreduction of newly diagnosed primary epithelial ovarian cancer , 2005 .

[21]  K. Brandt,et al.  The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma , 2004, Cancer.

[22]  J. Hendriks,et al.  The significance of circumscribed malignant mammographic masses in the surveillance of BRCA 1/2 gene mutation carriers , 2004, European Radiology.

[23]  B. Modan,et al.  Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in israel. , 2003, Gynecologic oncology.

[24]  R. Ozols.  Ovarian Cancer: American Cancer Society Atlas of Clinical Oncology , 2003 .

[25]  J. Satagopan,et al.  Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  G. Rustin,et al.  Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  B. Rosen,et al.  Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. , 2001, American journal of human genetics.

[28]  E. Fishman,et al.  A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography , 2000, Cancer.

[29]  J. Boyd,et al.  Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. , 2000, JAMA.

[30]  J. Ranstam,et al.  Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Zepp,et al.  Ovarian carcinoma: value of CT in predicting success of debulking surgery. , 1995, AJR. American journal of roentgenology.

[32]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[33]  J. Garber,et al.  Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. , 2012, Cancer genetics.

[34]  K. Hess,et al.  Association of BRCA 1 and BRCA 2 Mutations With Survival , Chemotherapy Sensitivity , and Gene Mutator Phenotype in Patients With Ovarian Cancer , 2011 .

[35]  S. Mocellin,et al.  Overall survival in BRCA-associated ovarian cancer: case-control study of an Italian series. , 2010, European Journal of Gynaecological Oncology.

[36]  D. Jung,et al.  Multidetector CT predictors of incomplete resection in primary cytoreduction of patients with advanced ovarian cancer , 2009, European Radiology.

[37]  E. Friedman,et al.  Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  R. Mann,et al.  Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI , 2008, European radiology.

[39]  P. Schwartz,et al.  Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.